Cargando…

The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study

INTRODUCTION: Given the possibility of inadvertent bacterial contamination of salvaged blood, the use of cell salvage is relatively contraindicated in cases of reimplantation for chronic hip periprosthetic joint infection (PJI). However, there are no published data supporting this assertion. The pur...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zunhan, Yang, Xuetao, Zhao, En-Ze, Wan, Xufeng, Cao, Guorui, Zhou, Zongke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832772/
https://www.ncbi.nlm.nih.gov/pubmed/35148802
http://dx.doi.org/10.1186/s13018-022-02955-3
_version_ 1784648788783136768
author Liu, Zunhan
Yang, Xuetao
Zhao, En-Ze
Wan, Xufeng
Cao, Guorui
Zhou, Zongke
author_facet Liu, Zunhan
Yang, Xuetao
Zhao, En-Ze
Wan, Xufeng
Cao, Guorui
Zhou, Zongke
author_sort Liu, Zunhan
collection PubMed
description INTRODUCTION: Given the possibility of inadvertent bacterial contamination of salvaged blood, the use of cell salvage is relatively contraindicated in cases of reimplantation for chronic hip periprosthetic joint infection (PJI). However, there are no published data supporting this assertion. The purpose of the current study was to compare the reinfection rate and rate of postoperative allogeneic blood transfusion (ABT) in second-stage reimplantation for PJI with or without intraoperative cell salvage reinfusion. MATERIALS AND METHODS: We identified 125 patients who underwent two-stage exchange for chronic hip PJI between November 2012 and April 2019. The groups of patients who had (n = 61) and had not (n = 64) received intraoperative cell salvage reinfusion were compared with respect to the curative infection-free rate. Moreover, we compared the need for postoperative ABT and identified independent factors associated with ABT using multiple regression analysis. RESULTS: The log-rank survival curve with an endpoint of infection eradication failure was not significantly different between the cell salvage group (98.4%, 95% CI 95.3–99.9%) and the control group (95.3%, 95% CI 90.2–99.9%) at one year (log rank, P = .330). The rates of postoperative ABT in the cell salvage group were significantly lower than those in the control group (11.5% vs 26.6%, P = .041). In multivariable models, patient age, body mass index, preoperative hemoglobin level, and intraoperative cell salvage were independent predictors of ABT exposure (P < .05). CONCLUSIONS: The use of cell salvage during reimplantation in two-stage exchange for chronic hip PJI did not appear to increase the reinfection rate, while it significantly reduced the rate of postoperative allogeneic red blood transfusion. Greater age, lower BMI, lower preoperative hemoglobin, and non-intraoperative cell salvage reinfusion were associated with higher rate of allogeneic red blood transfusion.
format Online
Article
Text
id pubmed-8832772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88327722022-02-15 The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study Liu, Zunhan Yang, Xuetao Zhao, En-Ze Wan, Xufeng Cao, Guorui Zhou, Zongke J Orthop Surg Res Research Article INTRODUCTION: Given the possibility of inadvertent bacterial contamination of salvaged blood, the use of cell salvage is relatively contraindicated in cases of reimplantation for chronic hip periprosthetic joint infection (PJI). However, there are no published data supporting this assertion. The purpose of the current study was to compare the reinfection rate and rate of postoperative allogeneic blood transfusion (ABT) in second-stage reimplantation for PJI with or without intraoperative cell salvage reinfusion. MATERIALS AND METHODS: We identified 125 patients who underwent two-stage exchange for chronic hip PJI between November 2012 and April 2019. The groups of patients who had (n = 61) and had not (n = 64) received intraoperative cell salvage reinfusion were compared with respect to the curative infection-free rate. Moreover, we compared the need for postoperative ABT and identified independent factors associated with ABT using multiple regression analysis. RESULTS: The log-rank survival curve with an endpoint of infection eradication failure was not significantly different between the cell salvage group (98.4%, 95% CI 95.3–99.9%) and the control group (95.3%, 95% CI 90.2–99.9%) at one year (log rank, P = .330). The rates of postoperative ABT in the cell salvage group were significantly lower than those in the control group (11.5% vs 26.6%, P = .041). In multivariable models, patient age, body mass index, preoperative hemoglobin level, and intraoperative cell salvage were independent predictors of ABT exposure (P < .05). CONCLUSIONS: The use of cell salvage during reimplantation in two-stage exchange for chronic hip PJI did not appear to increase the reinfection rate, while it significantly reduced the rate of postoperative allogeneic red blood transfusion. Greater age, lower BMI, lower preoperative hemoglobin, and non-intraoperative cell salvage reinfusion were associated with higher rate of allogeneic red blood transfusion. BioMed Central 2022-02-11 /pmc/articles/PMC8832772/ /pubmed/35148802 http://dx.doi.org/10.1186/s13018-022-02955-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Liu, Zunhan
Yang, Xuetao
Zhao, En-Ze
Wan, Xufeng
Cao, Guorui
Zhou, Zongke
The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study
title The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study
title_full The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study
title_fullStr The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study
title_full_unstemmed The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study
title_short The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study
title_sort use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832772/
https://www.ncbi.nlm.nih.gov/pubmed/35148802
http://dx.doi.org/10.1186/s13018-022-02955-3
work_keys_str_mv AT liuzunhan theuseofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT yangxuetao theuseofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT zhaoenze theuseofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT wanxufeng theuseofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT caoguorui theuseofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT zhouzongke theuseofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT liuzunhan useofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT yangxuetao useofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT zhaoenze useofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT wanxufeng useofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT caoguorui useofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy
AT zhouzongke useofcellsalvageduringsecondstagereimplantationforthetreatmentofchronichipperiprostheticjointinfectionaretrospectivecohortstudy